Skip to content
DataLookout
Start free
Menu

NCT07838389

Evaluation of Donor-Derived B Cell Infusions in Patients With Amyotrophic Lateral Sclerosis (ALS)

StatusNot Yet Recruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Infusion associated adverse events of special interest
Timeframe: Up to 6 months after 2nd infusion
Evidence of host rejection of infused cells
Timeframe: Within 4 weeks of 2nd infusion

Arms and interventions

ALS patients receiving infusions of haploidentical donor B cellsExperimental

ALS patients receiving infusions of haploidentical donor B cells between 200 million and 1 billion cells per infusion with the second infusion 60 days after the first.

Biologicals: B cell infusion

Sites

1 site in 1 country

  • Sean M. Healey and AMG Center for ALS at Massachusetts General HospitalBoston, Massachusetts, United States